Akesobio
China - ZhongshanBiotechnology
Focus: Akesobio is a China-based biotechnology company specializing in antibody therapies with a focus on oncology, currently generating revenue primarily from VONJO (pacritinib), a tyrosine kinase inhibitor. The company operates as a public entity with a diversified pipeline spanning 10 programs across Phase 1–3 development.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Akesobio
AI assessmentNot HiringNo open roles listed right now. Follow Akesobio to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Akesobio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
1 in 5yr
VONJO
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Help build intelligence for Akesobio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.